The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

REMINYL XL 16 mg prolonged-release capsules, hard

Takeda Pharmaceuticals International AG Ireland BranchPA23211/003/003

Main Information

Trade NameREMINYL XL 16 mg prolonged-release capsules, hard
Active SubstancesGalantamine hydrobromide
Dosage FormProlonged-release capsule, hard
Licence HolderTakeda Pharmaceuticals International AG Ireland Branch
Licence NumberPA23211/003/003

Group Information

ATC CodeN06DA Anticholinesterases
N06DA04 galantamine


License statusAuthorised
Licence Issued19/11/2004
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back